Skip to content
mapperlab
← Dashboard
Stock

VCEL

VERICEL CORPORATION
Health CareBiotechnologyLatest close $357 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
8
Current + past
New this quarter
1
Exited this quarter
1

Marquee-fund ownership over time

Aug 9, 2024May 15, 2025Feb 13, 2026May 15, 2026
Now
7

This quarter's activity

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$46$35-24%
Citadel Advisors$45$35-23%
D.E. Shaw$45$35-23%
AQR Capital Management re-entered$45$35-23%
Millennium Management re-entered$45$35-23%
Two Sigma Investments$40$35-13%
Point72 Asset Management$37$35-5%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Bridgewater Associates→ $33-8%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Vericel Corp. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
5
Filings · last 90d
14
Total on file
375
Recent SEC buffer
Most recent
Jun 4, 2026

30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 375 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · VERICEL CORPORATION

Annual figures sourced directly from VERICEL CORPORATION's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$276.26M
FY2025+16% YoY
Net income
$16.52M
FY2025+59% YoY
EPS (diluted)
$0.3200
FY2025+60% YoY
Free cash flow(?)
$24.75M
FY2025+500%+ YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Vericel Corp — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Renaissance TechnologiesQ2 2026open$33$35+5%
AQR Capital ManagementQ1 2026open$37$35-5%
Point72 Asset ManagementQ1 2026open$37$35-5%
Bridgewater AssociatesQ1 2026Q2 2026$36$33-8%
Two Sigma InvestmentsQ4 2025open$40$35-13%
Millennium ManagementQ4 2025open$40$35-13%
AQR Capital ManagementQ2 2025Q4 2025$41$40-4%
Citadel AdvisorsQ3 2024open$45$35-23%
D.E. ShawQ3 2024open$45$35-23%
AQR Capital ManagementQ3 2024Q1 2025$45$57+26%
Millennium ManagementQ3 2024Q2 2025$45$41-8%
Renaissance TechnologiesQ3 2024Q3 2025$46$38-17%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.